Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . 国药 集团 SINOPHARM CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO . LIMITED 中國 中藥 控股 有限公司 ( Incorporated in Hong Kong with limited liability ) ( Stock Code : 570 ) ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 The board ( the " Board " ) of directors of China Traditional Chinese Medicine Holdings Co. Limited ( the “ Company ” ) is pleased to present the unaudited consolidated results of the Company and its subsidiaries ( collectively referred to as the “ Group ” ) for the six months ended 30 June 2021 ( the “ Reporting Period ” ) as follows : RESULTS HIGHLIGHTS RMB'000 Period ended 30 June 2021 2020 RMB'000 Change Revenue - Concentrated TCM granules - Finished drugs - TCM decoction pieces 5,321,498 4,569,912 16.4 % 1,755,089 1,304,332 34.6 % 707,672 566,999 24.8 % - TCM healthcare complex 62,815 42,185 48.9 % - Local TCM integrated operation Total 302,277 171,891 75.9 % 8,149,351 6,655,319 22.4 % Gross profit 5,002,764 4,016,854 24.5 % Adjusted EBITDA 1,673,332 1,404,058 19.2 % Operating profit 1,315,660 1,108,125 18.7 % Profit for the period 1,006,679 830,197 21.3 % Profit attributable to equity holders of the Company 929,828 732,020 27.0 % Basic earnings per share ( RMB cents ) 18.46 14.54 27.0 % Proposed interim dividend per share ( HK cents ) 6.66 N / A 1